早期帕金森病中脑网络动态的演变,以及轻度认知障碍
Chunguang Chu1, Zhen Zhang1, Jiang Wang1
1School of Electrical and Information Engineering, Tianjin University, Tianjin, 300072 China.
Cognitive neurodynamics
|June 2, 2023
概括
在早期帕金森病 (PD) 中,轻度认知障碍 (MCI) 扰乱了大脑网络动态. 连接叶-叶-叶的特定子网络显示灵活性降低,与患有MCI的PD患者的认知能力下降相关.
科学领域:
- 神经科学是一个神经科学.
- 认知神经学 认知神经学
- 计算精神病学是一种计算精神病学.
背景情况:
- 轻度认知障碍 (MCI) 是早期帕金森病 (PD) 的常见非运动症状.
- 在PD中MCI的潜在神经机制,特别是关于功能性大脑网络动态的基础神经机制,仍然不太了解.
- 了解这些动态对于PD的早期诊断和干预至关重要.
研究的目的:
- 研究轻度认知障碍 (MCI) 在早期帕金森病 (PD) 中如何表现在空间分布的功能大脑网络的动态相互作用中.
- 确定特定的大脑网络特征,以区分患有或没有MCI的早期PD患者.
- 探索大脑网络动态变化与早期PD认知障碍严重程度之间的关系.
主要方法:
- 利用机器学习方法与个性化的滑动窗口算法来分析静止电脑电图 (EEG) 数据.
- 在33名早期PD患者 (13名患有MCI,20名没有MCI) 中,追踪了功能性大脑网络中的时间变化和重叠子网络.
- 解码了大脑子网络的动态相互作用和表达模式,以确定与MCI相关的变化.
主要成果:
- 确定了特定的子网络,在脑叶之间具有动态变化的和集成的相互作用.
- 观察到,在早期患有MCI的PD患者中,短暂的,灵活的子网络切换减少了.
- 一个连接叶-叶-叶的子网络显示MCI患者的表达和灵活性下降,与认知障碍相关.
- 在个人层面上,MCI与功能性大脑网络动态中的子网络的中断和较慢的进化有关.
结论:
- 早期帕金森病的轻度认知障碍的特点是异常的动态相互作用和功能性大脑网络的大规模变化.
- 特定子网络的灵活性降低和动态变化,特别是涉及叶-叶-叶的子网络,可以作为PD中MCI的潜在生物标志物.
- 这些发现为早期PD认知障碍的神经基础提供了新的见解,并强调了动态网络分析的重要性.
更多相关视频
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.7K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.9K
相关概念视频
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Parkinson's Disease: Overview
614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
Parkinson's Disease: Treatment
308
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
308
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
